Autologous hMSCs

BIOLOGICAL2 trials

Sponsors

Joshua M Hare

Conditions

Chronic Ischemic Left Ventricular DysfunctionMyocardial InfarctionNon-ischemic Dilated Cardiomyopathy

Phase 1

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

CompletedNCT01392625

Joshua M HareNon-ischemic Dilated Cardiomyopathy

Start: 2011-05-19End: 2017-08-28Updated: 2018-02-15

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

WithdrawnNCT02503280

Joshua M HareChronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction

Start: 2025-03-01End: 2032-03-31Updated: 2020-10-22

Related Papers

Mesenchymal Stem Cell Secretion of SDF-1α Modulates Endothelial Function in Dilated Cardiomyopathy

Frontiers in Physiology2019-09-2427 citations

Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy.

2018-07-1228 citations

Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy

Journal of the American College of Cardiology2016-11-14341 citations